X

Trial Profile

A Phase 1 Study of Safety and Tolerability of AutoSynVax Vaccine as a Single Agent in Subjects With Advanced Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 29 May 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AutoSynVax (Primary) ; QS 21
Indications Cancer; Solid tumours
Focus Adverse reactions
Sponsors Agenus

Most Recent Events

08 Jan 2020 Status changed from active, no longer recruiting to discontinued.
06 Nov 2018 According to an Agenus media release, the Safety and tolerability data will be presented at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting.
07 Nov 2017 According to an Agenus media release, immunological readouts expected in patients with advanced malignancies in 4Q 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com